CHAIN Biotechnology specializes in the delivery of proteins and peptides to the lower gut for immunotherapeutic and prophylactic purposes. Based at MediCity Nottingham, CHAIN develops oral vaccines and immuno-therapies targeting the lower gastrointestinal tract using a Clostridium based delivery system. The company's Clostridium Assisted Drug Development platform (CADD) technology is based on a highly effective Clostridium bacterial strain that is used as a human probiotic. The strain is engineered to deliver carefully selected proteins or peptides targeting specific indications, whilst simultaneously secreting metabolites that play key roles in gut and immune system homeostasis. The engineered strains target the systemic and mucosal immune system, by producing the selected proteins and peptides in situ, while growing in the lower gastrointestinal tract. The CADD platform supports oral drug delivery that is both targeted and controllable. In addition, the company's live biotherapeutics can be manufactured easily and cost-effectively and are highly stable with no cold chain logistics.